What I would hope to achieve as an Ordinary Council Member I would like to commit myself to getting more attention for screening for early CKD and prevention of CKD progression on a general population level. The number of subjects on dialysis or living with a functioning kidney graft is continuously growing, with important consequences for the persons affected and with large societal impact. This makes clear that prevention is needed. Population screening and early prevention may be part of the answer. This topic deserves more attention from the nephrological community, but definitely also from national and EU politicians, health care policy makers and clinical colleagues. It will be one of the challenges for our medical specialty to get the message of early CKD as important risk factor under the attention across Europe. When elected as Council Member I hope to be of help to achieve this.
Prof Ronald Gansevoort
Nephrology, University Medical Center Groningen (UMCG), the Netherlands (2000-2002); Clinical
Pharmacology, UMCG and Western Infirmary, Glasgow, United Kingdom (1999-2001); Residencies
UMCG and Twenteborg Hospital, Almelo, the Netherlands (1994-1999); Medical School, University
of Groningen and Sumve Hospital, Mwanza, Tanzania (1982-1989).
Program leader Groningen Kidney Center, UMCG (2018-present); Professor of Internal Medicine,
UMCG (2015-present); Chair PREVEND study (2011-present); Associate professor in Nephrology,
UMCG (2009-2015); Coordinator PREVEND study (2003-2011); Nephrologist, UMCG
(2002-present); Rapporteur for the Dutch Medicines Evaluation Board (1992-1994); Research
Fellow, Division of Nephrology, UMCG (1989-1994).
My work in the field of CKD and ADPKD has been instrumental in the development of the novel
KDIGO and WHO definition and classification of CKD, the development of novel endpoints for RCTs in Nephrology (lesser decreases in eGFR than doubling of sCreat, slope in eGFR and decrease in albuminuria) and the first registered treatment for ADPKD (tolvaptan).
Publications (peer reviewed publications, first or senior author) – 5 most important
(I). Meijer, Visser, van Aerts … and Gansevoort. Effect of lanreotide on kidney function in patients
with ADPKD: The DIPAK 1 Trial. JAMA. 2018;320:2010-2019. (II). Gansevoort, Correa-Rotter,
Hemmelgarn … and Wen. Chronic kidney disease and cardiovascular risk: epidemiology,
mechanisms, and prevention. Lancet. 2013;382:339-52. (III). Shlipak MG, Matsushita K, Ärnlöv J … and Gansevoort RT. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932-43. (IV). Matsushita, van der Velde, Astor … and Gansevoort. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-81. (V). Gansevoort, de Zeeuw, de Jong. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-7.
Fellow of the ASN (2018); Distinguished Fellow of the ERA EDTA (2015); US Kidney Foundation
Distinguished International Medal (2011); Dutch Society for Nephrology Award (1996); PhD thesis, cum laude (1995).
Contributions to the ERA-EDTA and/or to national/ international nephrology
Since 15 years various invited lectures at the meetings of the ERA-EDTA, ASN and ISN. Since 6
years Board Member of the Dutch Society of Nephrology. (Past) Board member of the Scientific
Advisory Boards of the Dutch Kidney and Heart Foundations. (Past) member of Steering Committee of various international RCTs in ADPKD and CKD (TEMPO, REPRISE, DIPAK 1, STAGED PKD, ARTS-DN, FIDELIO, FIGARO), observational studies (PREVEND, DIPAK Obs, EuroCYST) and
consortia (CKD Prognosis Consortium, DIPAK). Published over 475 peer reviewed manuscripts and supervised 28 PhD theses.
Member of the editorial boards of Nature Compr Clin Med (2019-present); NDT (2011-present);
AJKD (2011-present); cJASN (2010-present); Dutch J Nephrol (2010-2015); J Nephrol (2007-present).